VivoSeq
Infectious Disease

Pertussis

1

Pipeline Programs↗

0

Active Trials↗

1

Companies Involved↗

Pertussis is an early-stage landscape with 1 program across 1 company. The most active players are ILiAD Biotechnologies.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

91/100

Attrition Rate

8/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

I

ILiAD Biotechnologies

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 11

Bordetella Pertussis D420

Dalhousie University

Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

13

clinical trials

Completed10 · 77%
Unknown status2 · 15%
Terminated1 · 8%

Clinical Trials

Trial Activity

13 trials

Immunising Mums Against Pertussis 3
Completed·SSt George's, University of London·N/A·NCT03578120·64 enrolled
Maternal Pertussis Wholecell Responses
Completed·SSt George's, University of London·Phase 2·NCT04589312·181 enrolled
A Phase I Clinical Study of a GamLPV, a Live Intranasal Bordetella Pertussis Vaccine
Completed·Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation·Phase 1·NCT03137927·36 enrolled
First Adult Safety Trial on Nasal Live Attenuated B. Pertussis Vaccine
Completed·IInstitut National de la Santé Et de la Recherche Médicale, France·Phase 1·NCT01188512·48 enrolled
Vanderbilt Pertussis Exposure Study: PEP in Vaccinated Healthcare Workers Following Pertussis Exposure
Completed·VVanderbilt University·N/A·NCT00469274·1,102 enrolled
Maternal Determinants of Infant Immunity to Pertussis
Completed·—·Phase 4·NCT05856396·200 enrolled
Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine
Completed·IInstitut National de la Santé Et de la Recherche Médicale, France·Phase 1·NCT02453048·54 enrolled
Viaskin Pertussis Vaccine Trial
Completed·DDBV Technologies·Phase 1·NCT03035370·102 enrolled
Pertussis Challenge Study in Adults Vaccinated With BPZE1
Completed·IILiAD Biotechnologies·Phase 2·NCT05461131·53 enrolled
Open-label, Phase 1, Dose-escalation Clinical Trial to Establish a Controlled Human Infection Model by Determining the Optimal and Safe Bordetella Pertussis Dose That Induces Mild Symptomatic Infection and Colonization in Healthy Adults
Completed·DDalhousie University·Phase 1·NCT05136599·79 enrolled
Pertussis Acellular Vaccine Adjuvanted With TQL1055
Terminated·AAdjuvance Technologies, Inc.·Phase 1·NCT04793620·72 enrolled
Gambia Pertussis Study (GaPs)
Unknown status·LLondon School of Hygiene and Tropical Medicine·Phase 4·NCT03606096·600 enrolled
Bordetella Pertussis Colonisation Challenge Study
Unknown status·UUniversity of Southampton·N/A·NCT03751514·80 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)